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Accepted 9 April 2019; Published online 19 April 2019AbstractObjective: The Core Outcome SeteSTAndards for Development (COS-STAD) contains 11 standards (12 criteria) that are deemed to be
the minimum design recommendations for all core outcome set (COS) development projects. Cancer is currently the disease area with the
highest number of published COSs and is a major cause of worldwide morbidity and mortality. The aim of this study was to provide a
baseline of cancer COS standards.
Study Design and Setting: Systematic reviews of COSs have identified 307 published COS studies. Cancer COSs were eligible for
inclusion. Two reviewers independently assessed each of the COSs against the 12 criteria.
Results: Forty-nine cancer COSs were included; none met all 12 criteria representing the 11 minimum standards assessed in this study
(range 5 4e11 criteria, median 5 6 criteria). All studies met the four scope standards, eight (16%) met all three standards for stakeholders
involved, and two (4%) met all four standards for consensus process standards.
Conclusion: With the exception of ‘‘scope’’ specification, there is much need for improvement. Poor reporting often made it chal-
lenging to assess whether minimum standards were met. The consensus process criteria were most difficult to assess, particularly those
that required an assessment of being a priori. This is the first application of COS-STAD criteria to studies that have developed COSs
and provides a baseline of cancer COS standards of development.  2019 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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To make well-informed decisions about health care, we
need to be able to compare and contrast research findings on
the basis of the same outcomes. Core outcome sets (COSs)
represent the minimum important outcomes that should be
measured and reported in all research studies for a specific
condition. The use of COSs will improve the quality of evi-
dence used in health care decision-making, ultimately trans-
lating to improved health care for patients. For COSs to be
successfully implemented, they need to be easily accessible
to researchers and other key groups, developed using rigorous
methods, and reported clearly. The Core Outcome Measures
in Effectiveness Trials (COMET) Initiative was set up to help
achieve this. The development and continued maintenance of
the COMET database [1,2], through rigorous systematic re-
views [3e7], means that COSs are now easily accessible to
users of COSs. The COMET Handbook advocates the use of
rigorous methods through an accumulation of current knowl-
edge in the area of COS development and will be updatedess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 No core outcome set (COS) met all of the 12
criteria representing the 11 minimum standards as-
sessed in this study (range5 4e11 criteria, median
5 6 criteria).
 Poor reporting often made it challenging to assess
whether the minimum standards had been met.
What this adds to what was known?
 This is the first application of Core Outcome Set
eSTAndards for Development (COS-STAD) criteria
to studies that have developed COSs and provides a
baseline of cancer COS standards of development.
 COS-STAD was not published until 2017; all
included COS studies were carried out before this
publication date. Therefore, this assessment is not
a criticism of these studies or the study authors,
but rather a baseline against which future compar-
isons of cancer COSs can be made.
What is the implication and what should change
now?
 This current review provides guidance on how to
compare a published COS to the standards
(Table 2). This will further facilitate users to
assess whether a COS has been well developed.
 This study identified the need to separate standard
number 9 into two criteria, considering scoring
process and consensus definition separately. We
recommend this separation for future users of
COS-STAD.
E. Gargon et al. / Journal of Clinperiodically to continue to inform good methodological
practice in this area [8]. Furthermore, the Core Outcome
SeteSTAndards for Development (COS-STAD) recom-
mendations have been established to improve the methodo-
logical approach for developing COSs and help users to
assess whether a particular COS has been developed using
a reasonable approach [9].
Research in the area of COS development is becoming
more prevalent, but it is still quite new; we would therefore
expect improvements in methodological standards in the
coming years. To be able to assess this, however, a baseline,
against which we can compare future quality of COS devel-
opment and measure improvements in methodological stan-
dards, is necessary. COSs are developed across a wide range
of disease areas. Cancer is currently the disease area with the
highest number of published COSs. Furthermore, cancer is a
major cause of worldwide morbidity and mortality, hassubstantial variability in populations and treatments, and
covers a wide range of diverse clinical areas. Treatments
aim to cure the disease but are associated with multiple side
effects; trials are commonly performed, and major clinical
oncology organizations exist worldwide. It is essential to
ensure that outcomes in cancer trials reflect issues of impor-
tance to patients and health care professionals through the
use of well-developed COSs. The aim of this study was
therefore to provide a baseline of cancer COS standards of
development against which future comparisons can be made.2. Methods
2.1. Identification of COS studies
As of the end of 2017, a regularly updated systematic re-
view of COSs [3e7] had identified 307 published COSs for
research studies covering a wide range of different health
areas. Only COSs developed for cancer were eligible for in-
clusion in this evaluation.
2.2. Pilot study
COS-STAD contains 11 standards that are deemed to be
the minimum design recommendations for all COS devel-
opment projects [9]. The recommendations focus on three
key domains: scope, stakeholders, and consensus process.
A pilot study was carried out to inform the process of
assessment used in this study. One COS was randomly
selected. Three of the authors (E.G., P.R.W., and J.J.K.)
independently read the COS and made an assessment against
each of the 11 criteria listed in Table 1. Assessments were
compared, and a discussion occurred between the three au-
thors to define how the process should be applied. This
included the criteria used for assessment and the sources
of information that would be used to identify supporting in-
formation. Following this, a further five randomly selected
COSs were independently assessed by two of the authors
(E.G. and J.J.K.), and the process was further refined. Of
note, it was agreed that criteria number 9 (‘‘A scoring pro-
cess and consensus definition is described a priori’’) would
be split into two for assessment purposes. It became
apparent that in the five COSs assessed in the pilot study that
a study team could describe an a priori definition for one of
these only (e.g., provide a description of a scoring process
but not provide a consensus definition or vice versa), result-
ing in different assessments for each part of this criterion and
should therefore be assessed separately. Hereafter, they will
be referred to as 9a (scoring process) and 9b (consensus defi-
nition). A total of 12 criteria were therefore assessed in this
study, representing the 11 minimum standards.
2.3. Process
Two reviewers (E.G. and J.J.K.) independently assessed
each of the cancer COSs against the 12 criteria of
Table 1. Original COS-STAD criteria
Domain Standard number Standard
Scope specification 1 The research or practice setting(s) in which the COS is to be applied
2 The health condition(s) covered by the COS
3 The population(s) covered by the COS
4 The intervention(s) covered by the COS
Stakeholders involved 5 Those who will use the COS in research
6 Health care professionals with experience of patients with the condition
7 Patients with the condition or their representatives
Consensus process 8 Initial list of outcomes considered both health care professionals’ and patients’ views
9 A scoring process and consensus definition was described a priori
10 Criteria for including/dropping/adding outcomes were described a priori
11 Care was taken to avoid ambiguity of language used in the list of outcomes
Abbreviations: COS-STAD, Core Outcome SeteSTAndards for Development.
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that standard), no (not meeting that standard), or unsure
(it was unclear whether the criteria had been met). Further
details of the assessment are described in Table 2.
Verbatim text was extracted to support the assessment
being made and to aid discussion. Assessments were
compared, and a third reviewer consulted where there
was uncertainty. P.R.W. and J.M.B. were consulted for
methodological queries, and J.M.B. (surgical oncologist),
for clinical queries. Where the development process was
described across multiple articles for an individual COS,
a global assessment was made for each of the standards.
2.3.1. Sources of information
Articles describing the development of the COS were
eligible for providing supporting information for each of
the standards. This included main study publications and
protocols. The COMET database was not used as a source
of information in this study as it is a secondary source of
information (populated by the systematic reviews used in
this study to identify cancer COSs) and does not contain
any additional details necessary for this study.
2.4. Data analysis and presentation of results
The median and range were used to summarize the 12
criteria (representing the 11 minimum standards) met
across all of the included cancer COS studies. Percentage
frequencies were used to report the number of studies that
met each standard.3. Results
Forty-nine cancer COSs were included. An overview of
the minimum standard assessments is provided in Table 3,
and by study in Appendix 1. No COS met all of the 12
criteria representing the 11 minimum standards assessed
in this study (range 5 4e11 criteria, median 5 6 criteria).3.1. Scope specification
All studies met all four standards for scope.3.1.1. Standard number 1: the research or practice set-
ting(s) in which the COS is to be applied
All studies met this criterion: 40/49 (82%) stated that the
COS was intended for use in clinical trials, 4/49 (8%) stated
that the COS was intended for use in clinical research, two
(4%) stated that it was intended for use in clinical trials and
routine clinical practice, and three (6%) for research and
routine clinical practice.3.1.2. Standard number 2: the health condition(s)
covered by the COS
All studies met this criterion. Five COSs were developed
for cancer (nonspecific), and four specifically for complica-
tions of the treatments of cancer. Nine COSs were devel-
oped for prostate cancer, five for cancer of the colon and/
or rectum, and three for ovarian cancer. Two were devel-
oped for nonesmall cell lung cancer, two for Hodgkin’s
and non-Hodgkin’s lymphomas, and two COSs were devel-
oped for acute myeloid leukemia. The remaining seventeen
unique cancer COS areas are listed in Appendix 2.3.1.3. Standard number 3: the population(s) covered by
the COS
All studies met this criterion. In 10 of the cancer COSs,
it was not explicitly stated that the COS was intended for an
adult population only, but this was assumed because the
cancer covered by the COS was an adult-only cancer
(e.g., prostate cancer). Further assumptions were made for
an additional thirteen COSs that related to cancers that
may occur in children and adults but did not make any
statement about the population that the COS was intended.
These 13 COSs were deemed to be implicitly for adults on-
ly because they did not refer to children specifically.
Table 2. Assessment criteria: guidance on how to compare a published COS to the standards
Domain
Standard
number Standard Features to be considered Standard met
Unclear whether
standard is met Standard not met
Scope
specification
1 The research or
practice setting(s)
in which the COS
is to be applied
should be
considered
Descriptions include (but
not limited to) health
research, specific study
types (e.g., trials,
observational studies,
and longitudinal
studies), routine care,
audit, and registries.
The developed COS
might apply to a single
setting or a
combination of
settings.
Evidence that the
setting(s) (or
context of use) in
which the COS is
to be applied has
been considered.
The setting(s) (or
context of use) in
which the COS is to
be applied is unclear
or is not described.
An explicit
statement that
this was not
considered.
2 The health
condition(s)
covered by the
COS should be
considered
This could be general
(e.g., cancer) or
specific (e.g., lung
cancer).
Evidence that the
health
condition(s) has
been considered.
The health condition(s)
is unclear or is not
described.
An explicit
statement that
this was not
considered.
3 The population(s)
covered by the
COS should be
considered
Characteristics should be
relevant to the
population. The
following were
considered for cancer
COSs:
1 Disease stage
2 Age of population
Evidence that the
population has
been considered.
Population
characteristics are
discussed (e.g., in the
introduction or
discussion of the
article) but not in the
context of the COS
being developed.
Population is unclear or
not described.
An explicit
statement that
this was not
considered.
4 The intervention(s)
covered by the
COS should be
considered
1 This could be all/any
intervention or spe-
cific intervention
types (e.g., drug,
surgery)
Evidence that the
intervention has
been considered.
Interventions are
discussed (e.g., in the
introduction or
discussion of the
article) but not in the
context of the COS
being developed.
Intervention is unclear
or not described.
An explicit
statement that
this was not
considered.
Stakeholders
involved
5 Those who will use
the COS in
research
Descriptions include
(but not limited to) the
following:
1 Clinical trialists
(including trial inves-
tigators, members of
trial groups)
2 Researchers
(including methodolo-
gists, experts with
expertise in the
conduct of studies,
scientists)
3 Industry
representatives
COS article includes
description of i.
OR ii. OR iii.
It was not clear whether
those who will use the
COS in research were
included.
It was clear that
those who will use
the COS in
research were not
included.
6 Health care
professionals with
experience of
patients with the
condition
Health care professionals
(including all
disciplines such as
oncologists, urologists,
pharmacists,
surgeons, nurses,
etc.)b
COS article includes
description of
health care
professionals.
It was not clear whether
health care
professionals with
experience of patients
with the condition
were included.
It was clear that
health care
professionals with
experience of
patients were not
included.
(Continued )
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Table 2. Continued
Domain
Standard
number Standard Features to be considered Standard met
Unclear whether
standard is met Standard not met
7 Patients with the
condition or their
representatives
Descriptions include
(but not limited to) the
following:
1 Patients with the
condition
2 Patient
representatives
3 Patient advocates
4 Parents
5 Carers
COS article includes
description of i.
OR ii. OR iii. OR iv.
OR v.
It was not clear whether
patients/patient
representatives were
included.
It was clear that
patients/patient
representatives
were not included.
Consensus
process
8 Initial list of
outcomes
considered both
health care
professionals’ and
patients’ views
1 Health care profes-
sionals (see standard
number 6 descriptors)
2 Patient (see standard
number 7 descriptors)
Initial list clearly
included i. AND ii.
It was not clear whose
views’ were
considered.
The initial list only
included i. OR ii.
The initial list did
not include either
view.
9a A scoring process
was described a
prioria
Any description of a
scoring system to rate
outcomes [8],
including (but not
limited to) the
following:
1 A Likert scale or
similar
2 Ranking of outcomes
3 Allocation of points
It does describe a
scoring process,
and it is clear that
this was a prioria
It does describe a
scoring process but
does not state
whether this was a
priori (or when it was
described/defined).
It does not mention a
scoring process.
It clearly has not
used a scoring
process.
It does mention a
scoring process,
but states this was
not a priori, or text
about methods
confirms it.
9b A consensus
definition was
described a prioria
There are numerous ways
to define the
consensus criteria,
commonly these relate
to a mean or median
value for each
outcome or a
percentage of
participants scoring an
outcome as important
[8].
It does provide a
definition of
consensus, and it
is clear that this
was a prioria.
It does mention
consensus (or a
synonym) or provides
a description of
definition, but it is not
clear whether this was
a priori/when it was
described/defined.
It does not mention
consensus.
It clearly has not
used consensus
methods.
It does mention
consensus (or a
synonym), does
provide further
description of
definition, but
states this was not
a priori, or text
about methods
confirms it.
10 Criteria for
including/
dropping/adding
outcomes were
described a prioria
A description of this
process (e.g., a
description of
including AND
dropping AND adding
outcomes).
It does include a
description of
including AND
dropping AND
adding outcomes,
as well as stating
this was a prioria.
It does include a
description of
including AND
dropping AND adding
outcomes but does
not state whether this
was a priori/when it
was described/
defined.
It does not include any
description about
including/adding/
dropping outcomes.
It does not describe all
three elements of
this criterion
(including AND
dropping AND adding
outcomes).
It does include a
description of
including/
dropping/adding
outcomes, but
states this was not
a priori, or text
about methods
confirms it.
(Continued )
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Table 2. Continued
Domain
Standard
number Standard Features to be considered Standard met
Unclear whether
standard is met Standard not met
11 Care was taken to
avoid ambiguity of
language used in
the list of
outcomes
Consideration for
language should be
taken into account
when describing
outcomes to different
stakeholder groups. An
example might be the
use of both plain
language descriptions
and medical terms,
with these tested in a
pilot study for
understanding [9].
A clear description
of methods/steps
taken to avoid
ambiguity of
language.
Some suggestion that
this may have been
done, but not clearly
described.
No evidence of
consideration given to
ambiguity of
language.
An explicit
statement that
this was not
considered.
Abbreviations: COS-STAD, Core Outcome SeteSTAndards for Development.
a ‘‘a priori’’ as assessed by inclusion in a protocol or when stated ‘‘a priori’’ in the study report without a protocol to verify this (we have taken
this at face value).
b Clinicians, physicians, clinical investigators, and medical faculty were all different descriptors used for this in the cancer COS articles.
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by the COS
All studies met this criterion. Where the authors referred
to ‘‘evaluating treatments,’’ ‘‘cancer treatments,’’ or a COS
for ‘‘all trials,’’ we took this to mean all interventions.
Twenty-six (53%) COSs were developed for all/any inter-
ventions, eight (16%) for drug interventions, four (8%)
for procedures, three (6%) for surgical interventions, two
(4%) for screening, and the remaining six (12%) were for
other specific interventions (preoperative treatment strate-
gies, adjuvant treatment, larynx preservation strategies,
vaccination, exercise, and compression interventions).Table 3. Cancer COS minimum standard assessments (N 5 49)
Domain
Standard
number Standard
Scope specification 1 The research or practice setting(s
COS is to be applied
2 The health condition(s) covered b
3 The population(s) covered by the
4 The intervention(s) covered by th
Stakeholders involved 5 Those who will use the COS in re
6 Health care professionals with ex
patients with the condition
7 Patients with the condition or the
representatives
Consensus process 8 Initial list of outcomes considere
care professionals’ and patient
9a A scoring process was described
9b A consensus definition was descr
10 Criteria for including/dropping/ad
outcomes were described a pri
11 Care was taken to avoid ambiguit
used in the list of outcomes
Abbreviations: COS-STAD, Core Outcome SeteSTAndards for Developm3.2. Stakeholders involved
Eight (16%) studies met all three standards for stake-
holders involved.3.2.1. Standard number 5: those who will use the COS
in research
Thirty-six studies (74%) met this standard. Assumptions
were made based on the author affiliations (where it was
clear that the authors contributed to the COS development
process) or from the participant list affiliations when these
were provided, for 10 COSs. These 10 did not explicitlyStandard
met, n (%)
Standard
unclear, n (%)
Standard
not met, n (%)
) in which the 49 (100) 0 0
y the COS 49 (100) 0 0
COS 49 (100) 0 0
e COS 49 (100) 0 0
search 36 (74%) 7 (14) 6 (12)
perience of 35 (71) 8 (16) 6 (12)
ir 13 (27) 1 (2) 35 (71)
d both health
s’ views
8 (16) 5 (10) 36 (74)
a priori 5 (10) 44 (90) 0
ibed a priori 6 (12) 43 (88) 0
ding
ori
2 (4) 47 (96) 0
y of language 5 (10) 44 (90) 0
ent.
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assumed their inclusion when research institutions were
listed as affiliations.
Seven studies (14%) did not state that those who will
use the COS in research were involved in the COS devel-
opment and there was not enough evidence to support an
assumption being made; therefore, these were catego-
rized as unclear. Examples include where it was not
clear that the authors were the panel/participants
involved (and no other statement was made in relation
to stakeholders), participants were described as confer-
ence participants, but their backgrounds were not
described or they were described as ‘‘experts’’ without
any further description.
Six studies (12%) did not meet this standard. In these in-
stances, the stakeholders involved were clearly described
and did not include those who will use the COS in research.
3.2.2. Standard number 6: health care professionals
with experience of patients with the condition
Thirty-five studies (71%) clearly met this standard. As-
sumptions were made for eight COSs based on the author
affiliations (where it was clear that the authors are the group
who developed the COS) or from the participant list affili-
ations when these were provided. These eight did not
explicitly state that health care professionals (HCPs) were
included as participants, but we assumed their inclusion
when clinical care settings were listed as affiliations.
Eight (16%) did not state explicitly thatHCPswere involved
in the COS development and there was ambiguity in the
description provided; these were, therefore, categorized as un-
clear. Examples echoed those given for standard number 5.
Six studies (12%) did not meet this standard. In these in-
stances, the stakeholders involved were clearly described
and did not include HCPs in the process.
3.2.3. Standard number 7: patients with the condition or
their representatives
Thirteen studies (27%) met this standard. Eight studies
described including patient advocates or representatives,
and five included patients themselves. The number of pa-
tients in six of these studies was not reported. The percent-
age of patients with the condition or their representatives in
the remaining seven studies ranged from 9% to 68% in
studies with mixed participants.
Thirty-five studies (71%) did not meet this standard. In
these instances, the stakeholders involved were clearly
described and did not include patients in the process. It
was unclear in one study whether patients were included
as participants were described as conference delegates
without any further description.
3.3. Consensus process
Two studies (4%) met all four standards [five criteria]
for the consensus process.3.3.1. Standard number 8: the initial list of outcomes
considered both health care professionals’ and patients’
views
Eight studies (16%) met this standard. Two of these five
included patient-reported outcome (PRO) data (i.e., studies
that have collected data from patients using a patient-
reported outcome measure [PROM]) as well as trial data,
and therefore on face value have included the patient
perspective in the process.
Five studies (10%) did not clearly state whose views
were considered when generating the initial list and so,
therefore, have been categorized as unclear. One of these
studies included PROM items in the review (PROM
items only not PRO data). Patients may or may not have
been involved in the PRO development, but it was
beyond the scope of this study to research PROM devel-
opment; we cannot therefore say if they considered pa-
tients’ views.
Thirty-six studies (74%) did not meet this standard and
did not consider both HCPs’ and patients’ views when
generating the initial list of outcomes used in the COS
development. These studies considered trial data, clinical
trials literature, or clinical guidelines only (hence did not
consider patients’ views).
3.3.2. Standard number 9a: a scoring process was
described a priori
Five studies (10%) met this standard. It was unclear
whether the remaining 44 (90%) met this standard. Ten
studies described a scoring process, but it was not clear
whether this process was determined a priori; 28 studies
did not describe specific methods relating to scoring, and
six studies did not describe the methods used at all.
3.3.3. Standard number 9b: a consensus definition was
described a priori
Six studies (12%) met this standard. It was unclear
whether this standard was met for the remaining 43
(88%). In 26 studies, it was unclear whether the consensus
definition was defined a priori; eleven studies did not
describe a process of consensus and therefore did not pro-
vide a definition, and the remaining six studies did not
describe their consensus methods at all.
3.3.4. Standard number 10: criteria for including/drop-
ping/adding outcomes were described a priori
Two studies (4%) met this standard. It was unclear
whether this standard was met for the remaining 47 studies
(96%). The detail of all three elements of this standard was
not clearly described in six studies, and for two studies that
did describe this process, it was not possible to assess the a
priori element of this criterion. Thirty-three studies had no
description of this process, and six did not describe their
methods overall, making it impossible to assess whether
this criterion had been considered.
43E. Gargon et al. / Journal of Clinical Epidemiology 112 (2019) 36e443.3.5. Standard number 11: care was taken to avoid am-
biguity of language used in the list of outcomes
Five studies (10%) met this criterion. In one study, the
outcomes were formulated with examples in parentheses
for some PROs; and in another study, the patient represen-
tatives received a glossary of terms before completing the
survey. Although this information is limited as COS-
STAD is being applied retrospectively here, we have inter-
preted this as some consideration of the language used to
describe outcomes. This criterion was clearly met in the
other three studies, where the questionnaires were assessed,
by patients, for face validity and comprehension before use.
For 44/49 studies (90%), there was no evidence that care
was taken to avoid ambiguity of language, and therefore it
was unclear whether they met this criterion.4. Discussion
This is the first application of the COS-STAD criteria to
studies that have developed COSs. Forty-nine cancer COSs
were included. No COS met all of the minimum standards,
with most studies meeting half of the standards. However,
COS-STAD was not published until 2017, which was after
all of these studies started. Therefore, this assessment is not
a criticism of these studies or the study authors, but rather a
baseline against which future comparisons can be made.
Furthermore, this current review provides guidance on
how to compare a published COS to the standards
(Table 2). This will further facilitate users to assess whether
a COS has been well developed.
Standards in the scope domain were well met. One
explanation for this could be that these scope criteria are
synonymous with the ‘‘PIC’’ part of the PICO format that
is often used to formulate a research question [10]. For
the purposes of this study, there was an assumption that a
COS was developed for adults only unless stated otherwise.
This was deemed to be clinically relevant for cancer COSs,
and consideration should be given to other disease areas
and whether the same assumption is correct. When assess-
ing standards in the scope domain, we observed that multi-
ple COSs were developed for some cancers, for example,
nine COSs have been developed for prostate cancer alone.
At times, this may reflect unnecessary duplication, but
often they had relevant and appropriate differences in
scope; for example, differences in stage or type such as
advanced or localized cancer. COS-STAD can be used as
a tool to help users of COSs to assess whether a COS has
been well developed. Users will need to use their own judg-
ment regarding the applicability of the COS (scope) for the
purpose they require [9].
Most COS studies did include those who will use the
COS in research and HCPs in the development process,
whereas just over a quarter included patients or patient rep-
resentatives in the process. This is reflective of COSs in
general and is not a methodological problem specific tocancer. Recent research has shown an improvement in pa-
tient participation in more recently published COSs
[6,11]. Although thirteen studies did include patients in
COS development, there is still great variability in the level
of participation of patients in COS development. This also
needs to be taken into account when deciding if a COS was
well developed.
The consensus process standards were the most difficult
to compare against, particularly those that required an
assessment of being specified a priori. Only four studies
stated that they had a protocol, of which two were pub-
lished and one we were able to obtain from study authors.
In the remaining studies, because we were applying this
retrospectively, we took it at face value when the COS
report stated that something was specified a priori because
we were unable to verify this in a protocol. Although mak-
ing the protocol publicly available for a COS development
study was not agreed on as a COS-STAD minimum stan-
dard, it was suggested that the availability of a protocol
would ensure that the methods are explicitly documented
before the COS development project starts, thus promoting
research integrity and transparency of the finalized COS.
This will make it easier for users to assess the COS against
COS-STAD for future studies.
This study identified the need to consider the scoring
process and consensus definition separately. We recom-
mend this separation for future users of COS-STAD. With
regard to criteria 9a (scoring), an observation was that in
those that did not meet this standard, the method of devel-
opment used for consensus in all of these studies was some
form of meeting or workshop to decide on the COS, but
detailed description of what was done at those meetings
was missing. Further consideration is needed about the
applicability and suitability of this criterion for all methods
that might be used for COS development.
Standard number 10, the criterion for including/dropping/
adding outcomes, was only met by two studies. The a priori
part of the assessment was unclear for a further two studies,
but the majority did not mention anything about this process
or did not describe it in sufficient detail to be able to assess
whether this criterion was met. This suggests that perhaps
COS developers do not fully understand the implications
or importance of this aspect of the development process,
and detail might be lacking as it might be considered too
much information for publication. It should be noted that a
lack of reporting of methods does not necessarily mean that
these methodological aspects were not considered. This
standard is also reflected in the Core Outcome Set-STAn-
dards for Reporting (COS-STAR) as a reporting requirement
[12]. However, COS-STAR was not published until 2016,
which is after most of these included COS studies were pub-
lished. It is therefore unrealistic to expect these reporting
standards to be implemented in these studies, so it is to be
hoped that evidence of consideration of this criterion (and
indeed the other standards) will be included in study reports
in the future.
44 E. Gargon et al. / Journal of Clinical Epidemiology 112 (2019) 36e44COS-STAD focusses on the main design principles for
COS development, whereas COS-STAR is exclusive to
the reporting of COS studies. As already highlighted, issues
with reporting were one of the main limitations of this
study as it made it difficult, sometimes impossible, to assess
consideration of the COS-STAD standards. We did obtain
protocols when it was stated that a protocol was available,
but this was very few. As such, we were unable to distin-
guish development plans from poor final reporting. Further-
more, this meant that assumptions were sometimes made to
enable a judgment to be made. Another limitation was that
the studies being assessed were published before COS-
STAD and therefore could not have been informed by the
development standards. Another potential limitation is that
we identified cancer COSs from existing systematic re-
views of COSs and did not conduct a separate search. To
address this potential limitation, the list of COSs was re-
viewed by a relevant expert (J.M.B.) for completeness.
The inclusion of cancer/COS methodology experts was a
further strength of this study, as was the independent dual
extraction and assessment of data.
This study aimed to provide a baseline of cancer COS
standards of development against which future comparisons
can be made. With the exception of scope specification,
there is much need for improvement. Poor reporting made
it challenging to assess whether the minimum standards
had been met for all stakeholder involvement and consensus
process standards. With the publication of methodological
evidence [13,14] and guidance [8,9,15], as well as reporting
standards [12], improvement is expected over time.CRediT authorship contribution statement
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